Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04812561
Other study ID # NS_Bronch_01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 14, 2020
Est. completion date April 2021

Study information

Verified date March 2021
Source Chonbuk National University Hospital
Contact Soo Wan Chae, Ph.D., M.D.
Phone 82-63-259-3040
Email soowan@jbnu.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was conducted to investigate the effects of daily supplementation of Bronch™(mixture of extraction of Korean mint and licorice) on respiratory health.


Description:

This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. 60 subjects were randomly divided into Bronch™ group and a placebo group. It is to evaluate the changes in the displayed evaluation items when taking one pill twice a day, in comparison with taking a placebo.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date April 2021
Est. primary completion date April 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - Age 19-80 years at screening - nonsmoker - After fully hearing and fully understanding this clinical trials, those who agree to voluntarily decide to participate and to comply with the notice Exclusion Criteria: - Participants with clinically significant severe cardiovascular, endocrine, immune, respiratory, liver, biliary, renal and urinary tract, neuropsychiatry, musculoskeletal, inflammatory and hematologic and gastrointestinal disorders - Participants who have Body Mass Index(BMI) less than 18.5 kg/m^2 or more than 35 kg/m^2 - Participants who have taken medication or dietary supplements related to the respiratory disease within 1 months prior to screening - Participants with a history of antipsychotic medication use within 3 months prior to the screening examination - Participants who alcoholic or drug abuse suspected - Participants who have participated in the other human trials within 3 months before the screening test - Laboratory test by show the following results - AST, ALT > Reference range 3 times upper limit - Serum Creatinine > 2.0 mg/dL - Pregnancy or breast feeding - Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Bronch™
2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week
placebo
2 times a day, 1 pill for 1 time, after breakfast/dinner meal, for 12 week

Locations

Country Name City State
Korea, Republic of Clinical Trial Center for Functional Foods Chonbuk National University Hospital Jeonju Jeollabuk-do

Sponsors (1)

Lead Sponsor Collaborator
Chonbuk National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of CAT{Chronic obstructive pulmonary disease(COPD) Assessment Test} scores CAT were measured in study screening, visit 2(6 week), visit 3(12 week). CAT was developed for use as a way to assess the quality of life of COPD patients, consisting of eight items, each of which evaluates 0 to 5 points, and the sum of all eight item scores is the CAT score. The best quality of life is 0 points, and the worst is 40 points. screening, 6, 12 week
Primary Changes of BCSS(Breathlessness, Cough, and Sputum Scale) scores BCSS were measured in study visit 1(0 week), visit 2(6 week), visit 3(12 week). BCSS is a scale for evaluating symptoms of Breathlessness, cough, and sputum, which is a major symptom of COPD(Chronic obstructive pulmonary disease), and symptoms of Breathlessness, cough, and sputum are evaluated in five stages.
0, 6, 12 week
Secondary FVC(Forced vital capacity) The Forced vital capacity(FVC) was measured Flow rate discharged during the hard-working unit before and after the intervention. screening, 12 week
Secondary FEV1(Forced expiratory volume in 1 second) The Forced expiratory volume in 1 second(FEV1) was assessed before and after the intervention. screening, 12 week
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04170881 - CRESPI - Respiratory Health of Children in Daycare
Recruiting NCT04758845 - Clinical Study to Evaluate the Safety and Efficacy of New Probiotic Strains in Health Adults N/A
Completed NCT04368169 - The Effects of an Aromatic Botanical Extract on Respiratory Health. N/A